Physical activity is medicine: Prescribe it
Therapeutics Letter No. 137 (May-June 2022) is one of Therapeutics Initiative’s first evidence-based Letters that does not reference prescription drug therapy. The new Let
The Therapeutics Initiative Blog brings you news and information from the world of therapeutics. Bookmark this page to see our frequently refreshed content.
Therapeutics Letter No. 137 (May-June 2022) is one of Therapeutics Initiative’s first evidence-based Letters that does not reference prescription drug therapy. The new Let
Following recent patent expirations of originator biologics, their more affordable biosimilar versions became available. Switching patients from originator to its biosimilar as par
In our effort to make prescription drug use safer we at the TI are constantly on the alert for what is happening in the wider BC health system. While patients are often told to “
In Therapeutics Letter 136, just published last week, we ask a question some might find provocative: “How do YOU respond to Conflicts of Interest?” In professional edu
Statins and a Patient’s Perspective on Informed Decision-making Occasionally people read our Therapeutics Letters and contact us to share their experiences. These anecdotes are
A study published recently in PLOS One finds that cancer is increased with cumulative exposure to angiotensin-receptor blockers (ARBs). The authors carried out a meta-regression an
In our continued examination of drug safety warnings, researchers with UBC’s Therapeutics Initiative, and others found that warnings about heart risks associated with the ant
In July 2021 we published a Therapeutics Letter on tramadol and advised our readers that “Health Canada has announced that it will add tramadol to Schedule I of the Controlle
The Therapeutics Initiative is excited to extend a warm welcome to the newest member of our team, Dr. Anshula Ambasta, who joins us from Calgary, bringing with her a deep research
A new University of British Columbia study published in the journal Clinical Therapeutics has found that drug companies who sponsor clinical trials in Canada exert influence in som